ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

ACS Study Shows Reduced Mortality For Low T/N Brands

April 18, 1980

ACCC Asks More Community Representation, Clear Separation From Centers In New NCI Division

June 29, 1979

In Brief: Gregory Curt Nominated DCT Deputy DCC Seeks Occupational Cancer, Prevention Branch Chiefs

October 26, 1984

Rituximab Prolonged Survival Of CLL In Phase III Study

September 24, 2010

Gleevec Approval Sets Record For FDA Review: 73 Days

May 25, 2001

Workshop Calls For Improved Surgical Oncology Training Programs

December 2, 1983